5 September 2025 - The DoH has published a revised agenda for the November 2025 PBAC meeting.

There are a few major changes. The PBAC will review unresolved recommendations for:

• Cabotegravir (Apretude)
• Lenacapavir sodium (Sunlenca)
• Pembrolizumab (Keytruda)

Read PBS News